Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.42 - $138.81
Previous CloseN/A
Volume185.86K
Average Volume (3M)9.19M
Market Cap
$1.70B
Enterprise Value$2.38B
Total Cash (Recent Filing)$800.14M
Total Debt (Recent Filing)$1.35B
Price to Earnings (P/E)19.6
Beta0.72
Next Earnings
Oct 29, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding97,713,440
10 Day Avg. Volume7,439,101
30 Day Avg. Volume9,186,805
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue0.96
Enterprise Value/Gross Profit1.21
Enterprise Value/Ebitda54.06
Forecast
1Y Price Target
$23.96Price Target Upside37.78% Upside
Rating ConsensusHold
Number of Analyst Covering28
Bulls Say, Bears Say
Bulls Say
Financial StrategySRPT announced a strategic restructuring with pipeline prioritization with significant cost-cuts to ensure profitability, fulfills revolving debt covenants, and can repay its 2027 convert.
Liquidity ManagementSarepta announced a refinancing of $700.0M of the $1.1B convertible notes, extending maturity to 2030 and de-levering the balance sheet; this is viewed favorably and helps ease near-term liquidity concerns.
Product DevelopmentPreliminary data on siRNA assets in myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy have the potential to provide a much-needed lift to Sarepta's stock.
Bears Say
Financial BurdenEquity holders take the hit: nearly 10% dilution, higher interest, and a $103M cash drain.
Product SafetySarepta Therapeutics announced a second non-ambulatory Elevidys patient died from acute liver failure, leading to the suspension of all Elevidys shipments for non-ambulatory DMD patients.
Regulatory ChallengesThe company expects a formal FDA partial clinical hold on Elevidys due to recent patient deaths.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $10.41 and its highest was $138.81 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $1.70B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is in 43 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 06, 2025. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $0.832 by $1.058.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -0.64.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 97,713,440 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $1.89 in its last earnings report, beating expectations of $0.832. Following the earnings report the stock price went up 10.455%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$23.96 (37.78% Upside)
$23.96 (37.78% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 62%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.12%
12-Months-Change
Fundamentals
Return on Equity
-4.76%
Trailing 12-Months
Asset Growth
7.46%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics (SRPT) is a biopharmaceutical company focused on developing innovative therapies for rare diseases, primarily targeting genetic disorders such as Duchenne muscular dystrophy (DMD). The company operates in the biotechnology sector and is known for its pioneering work in gene therapy and RNA-targeted medicines. Sarepta's lead product candidates include exon-skipping therapies and gene replacement therapies designed to address the underlying causes of DMD and other genetic conditions.
SRPT Company Deck
SRPT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic restructuring, cost-saving measures, and a focused pipeline to strengthen Sarepta's financial position and future growth. However, challenges such as workforce reduction, hesitancy in ELEVIDYS adoption, and suspension of nonambulatory ELEVIDYS shipments present significant hurdles.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$23.96
▲(37.78% Upside)
Technical Analysis
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Ownership Overview
4.68% Insiders
17.61% Mutual Funds
21.78% Other Institutional Investors
28.48% Public Companies and Individual Investors